Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 16, 2017 at 5:00 p.m. Pacific Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
